Regeneron (REGN) -4.1%, although it's not obvious why. Q4 sales of Eylea, its eye treatment for...

|About: Regeneron Pharmaceuticals... (REGN)|By:, SA News Editor

Regeneron (REGN) -4.1%, although it's not obvious why. Q4 sales of Eylea, its eye treatment for wet age-related macular degeneration, were $276M. That's above estimates of $264.2M and brings the total for 2012 to $838M. Regeneron forecasts that U.S. sales will grow 50%, leading to annual revenue of $1.26B and already beating a Citigroup prediction that Eylea would generate peak annual sales of $1.1B in 2021. (Presentation for JPM conference)